These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33263263)

  • 21. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
    Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
    Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.
    ; Bowman L; Chen F; Sammons E; Hopewell JC; Wallendszus K; Stevens W; Valdes- Marquez E; Wiviott S; Cannon CP; Braunwald E; Collins R; Landray MJ
    Am Heart J; 2017 May; 187():182-190. PubMed ID: 28454801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
    Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
    J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
    Thomas T; Zhou H; Karmally W; Ramakrishnan R; Holleran S; Liu Y; Jumes P; Wagner JA; Hubbard B; Previs SF; Roddy T; Johnson-Levonas AO; Gutstein DE; Marcovina SM; Rader DJ; Ginsberg HN; Millar JS; Reyes-Soffer G
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1770-1775. PubMed ID: 28729361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anacetrapib as a potential cardioprotective strategy.
    Di Bartolo BA; Nicholls SJ
    Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.
    Wang SP; Daniels E; Chen Y; Castro-Perez J; Zhou H; Akinsanya KO; Previs SF; Roddy TP; Johns DG
    J Lipid Res; 2013 Oct; 54(10):2858-65. PubMed ID: 23898048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Arai H; Teramoto T; Daida H; Ikewaki K; Maeda Y; Nakagomi M; Shirakawa M; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Vaidya S; Blaustein RO
    Atherosclerosis; 2016 Jun; 249():215-23. PubMed ID: 27131642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits.
    Wu BJ; Li Y; Ong KL; Sun Y; Johns D; Barter PJ; Rye KA
    Sci Rep; 2019 Nov; 9(1):16183. PubMed ID: 31700015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Apr; 19(6):611-615. PubMed ID: 29498299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
    Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):628-36. PubMed ID: 25633313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
    Brousseau ME; O'Connor JJ; Ordovas JM; Collins D; Otvos JD; Massov T; McNamara JR; Rubins HB; Robins SJ; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1148-54. PubMed ID: 12117730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.